Meet the Marinus Team

Marinus Pharmaceuticals’ management team is committed to developing ganaxolone for treatment of drug-resistant seizures and neuropsychiatric disorders in both the hospital and home setting.

Board of Directors

Nicole Vitullo

Director, Chairman of the Board

Nicole Vitullo was appointed Chairman of the Board in August 2019 has served as a Director on our Board since September 2005.

Ms. Vitullo is a Partner at Domain Associates and has extensive experience in both public and private investing in biotech companies and liquidation/distribution strategies for public companies. For more than a decade, Ms. Vitullo was responsible for Domain Public Equity Partners L.P., a fund focused on private investments in public companies. Previous to Domain, Ms. Vitullo was senior vice president at Rothschild Asset Management, Inc., where she had responsibility for the U.S. public market investments of International Biotechnology Trust plc and Biotechnology Investments Limited. Prior to that, Ms. Vitullo served as the director of corporate communications and investor relations at Cephalon, a publicly traded biotechnology company, and held a number of positions at Eastman Kodak, including corporate development.

Ms. Vitullo was appointed Chairman of the Board in August 2019 has served as a Director on our Board since September 2005. Her current board memberships include Antios Therapeutics, Exalys, Inc., and Esperion Therapeutics. Previously, Ms. Vitullo served as Chairman of the Board at Achillion Pharmaceuticals (sold to Alexion) and served on the boards of Celator Pharmaceuticals (sold to Jazz Pharmaceuticals), Durata Therapeutics (sold to Activas PLC), Cerexa Therapeutics (sold to Forest Labs) and Calixa Therapeutics (sold to Cubist). Ms. Vitullo received her B.A. in mathematics and her M.B.A. in finance from University of Rochester.

Nicole Vitullo

Nicole Vitullo

Director, Chairman of the Board

 

Scott Braunstein, M.D.

Chief Executive Officer & Director

Scott Braunstein, M.D. was appointed Chief Executive Officer of Marinus in August 2019, executive chairman in February 2019 and has served on our board since September 2018.

Dr. Braunstein brings over 20 years of knowledge and experience from diverse biotechnology and pharmaceutical industry vantage points. Dr. Braunstein is currently an operating partner at Aisling Capital. He most recently served as chief strategy officer and chief operating officer at Pacira Biosciences, Inc. Prior to Pacira, Dr. Braunstein served as a healthcare portfolio manager at Everpoint Asset Management and spent 13 years with J.P. Morgan Asset Management as a healthcare analyst and managing director in the U.S. Equity team, and as portfolio manager of the JP Morgan Global Healthcare Fund responsible for managing investments in pharmaceuticals, biotechnology and medical devices.

Dr. Braunstein is currently on the board at Trevena, Inc. and Caribou Biosciences, Inc. He previously served on the boards of Constellation Pharmaceuticals (acquired by MorphoSys AG in July 2021), Ziopharm Oncology, Inc., Esperion Therapeutics, Inc. and Protara Therapeutics, Inc. Dr. Braunstein began his career as a practicing physician at the Summit Medical Group and as assistant clinical professor at Albert Einstein College of Medicine and Columbia University Medical Center. He earned his medical degree from the Albert Einstein College of Medicine and his B.S. from Cornell University.

Scott Braunstein 2

Scott Braunstein, M.D.

Chief Executive Officer & Director

 

Santiago Arroyo, M.D., Ph.D.

Director

Dr. Arroyo joined our Board in July 2021.

Dr. Arroyo brings more than 30 years of experience in academic neurology and pharmaceutical research and development. Before joining the pharmaceutical industry, Dr. Arroyo was an instructor in neurology at the Johns Hopkins Hospital and helped set up and run the epilepsy programs at the Medical College of Wisconsin and Hospital Clinic of Barcelona, Spain. Most recently, he served as Chief Medical Officer of Momenta Pharmaceuticals (acquired in 2020 by Johnson & Johnson). Prior to his role at Momenta Pharmaceuticals, Dr. Arroyo served as Chief Medical Officer of Boston Pharmaceuticals, focusing on the therapeutic areas of immunology, oncology and infectious diseases.

Dr. Arroyo also held the roles of Senior Vice President, Head of Clinical Research and Chief Medical Officer of Biotherapeutics and Pharmatherapeutics at Pfizer Inc., in the areas of pain and neuroscience, cardiovascular and metabolic disease, regenerative medicine and rare diseases. He was therapeutic area head for neurosciences, discovery medicine and clinical pharmacology at Bristol-Myers Squibb and neurology global therapeutic area head for Eisai Global Clinical Development. Dr. Arroyo currently sits on the Board of the Danish biopharmaceutical company, Lundbeck. He received his medical degree from the Autonomous University of Madrid and his Ph.D. from the University of Barcelona, Spain.

Santiago Hs

Santiago Arroyo, M.D., Ph.D.

Director

 

Chuck Austin

Director

Chuck Austin was appointed to our board of directors July 2020.

Mr. Austin has more than 25 years of experience in the life sciences sector, and has held numerous roles in supply chain operations, research and development, and engineering throughout his career with Johnson & Johnson. Prior to his appointment to Marinus’ Board of Directors, Mr. Austin served as Corporate Vice President, Global Supply Chain at Johnson & Johnson, where he was a member of the Johnson & Johnson Management Committee and was responsible for all manufacturing, logistics, quality, compliance, direct procurement, environmental, health and safety, and engineering and real estate for the corporation.

As Company Group Chairman of Ethicon Surgical Care – a Johnson & Johnson Company – Mr. Austin helped combine four separate operating units, re-engineer a global commercial model, and return the overall franchise to growth. He obtained a Bachelor of Science in Engineering from the United States Military Academy, West Point, New York, and served in the United States Army for over nine years. He currently serves on multiple boards in the medical and consumer spaces and is a principal in JK Advisors, a San Diego based firm focused on the medical space.

Charles Austin

Chuck Austin

Director

 

Michael R. Dougherty

Director

Michael R. Dougherty has served on our Board since February 2017.

Mr. Dougherty has over 35 years of experience in the pharmaceutical industry, most recently serving as executive chairman of Celator Pharmaceuticals, Inc. He previously held a number of senior positions in the industry, including chief executive officer of Kalidex Pharmaceuticals, Inc., president and chief executive officer at Adolor Corporation, president and chief operating officer of Genomics Collaborative, Inc., president and chief executive office at Genaera Corporation, and chief financial officer at Centocor, Inc.

Mr. Dougherty is currently on the Board of Directors at Trevena, Inc. and Idera Pharmaceuticals, Inc., and previously served as a member of the Boards of Directors of Foundation Medicine, Inc., Aviragen Therapeutics, Cempra, Inc., and Viropharma Incorporated. He received a bachelor’s degree in accounting from Villanova University.

Michael Dougherty

Michael R. Dougherty

Director

 

Elan Ezickson

Director

Elan Ezickson joined our Board in December 2019.

Mr. Ezickson brings extensive biopharmaceutical operational, strategic and capital formation expertise to Marinus’s board, most recently having served as the Chief Operating Officer and head of corporate development at Scholar Rock Holding Corporation, a clinical stage biotechnology company focused on novel oncology and rare disease treatments. At Scholar Rock, he directed corporate development, operations and strategy, and played a significant role in corporate finance, leading the company’s initial public offering. Prior to joining Scholar Rock, he served as Executive Vice President and Chief Operating Officer of Aveo Pharmaceuticals where he built and oversaw corporate development, commercial operations, technical operations, medical affairs, program management and legal functions and led capital raising and licensing efforts with multinational pharmaceutical companies.

Prior to Aveo, Mr. Ezickson was at Biogen in roles that included President of Biogen Canada, Program Executive and Associate General Counsel. He currently serves on the Boards of Directors of four biotechnology firms including Carmine Therapeutics, Tvardi Therapeutics, Ziopharm Oncology and Asylia Therapeutics. Mr. Ezickson holds a Bachelor of Arts degree in political science from Yale University and a Juris Doctorate from the Columbia University School of Law.

Elan Ezickson

Elan Ezickson

Director

 

Seth H.Z. Fischer

Director

Seth H.Z. Fischer has served on our Board since September 2016.

Mr. Fischer brings to the Board of Directors over 38 years of experience in the pharmaceutical and medical device industry, including 29 years in various leadership roles at Johnson & Johnson.
Mr. Fischer currently serves as a member of the Board of Directors of Agile Therapeutics, Inc. (AGRX), Spectrum Pharmaceuticals, Inc. (SPPI), and is also an advisor to MedHab, LLC. Previously, Mr. Fischer served as the Chief Executive Officer and as a Director of Vivus, Inc., a publicly traded biopharmaceutical company commercializing and developing innovative, next-generation therapies to address unmet needs in obesity, diabetes, sleep apnea and sexual health from September 2013 to December 2017. Prior to Vivus, Mr. Fischer served in various positions of increasing responsibility at Johnson & Johnson, most recently as Company Group Chairman, Johnson & Johnson and Worldwide Franchise Chairman of Cordis Corporation.

Prior to that, he served as Company Group Chairman, North America Pharmaceuticals, which included responsibilities for Ortho-McNeil Pharmaceuticals, Janssen and Scios. Prior to that, Mr. Fischer served as President of Ortho-McNeil Pharmaceuticals. Mr. Fischer’s operating responsibilities encompassed the commercialization of products in multiple therapeutic categories including Topamax® for epilepsy and migraines, neurologic, analgesic, anti-infective, cardiovascular, psychiatric and women’s health areas. From May 2013 to May 2019, Mr. Fischer also served on the Board of Directors of BioSig Technologies, Inc. 
Mr. Fischer earned a bachelor’s degree in general studies from Ohio University and served as a captain in the U.S. Air Force.

Seth Fischer

Seth H.Z. Fischer

Director

 

Tim M. Mayleben

Director

Tim M. Mayleben has served on our Board since December 2008.

Mr. Mayleben has more than two decades of executive leadership experience in the life sciences industry, most recently as President, CEO and Director of Esperion Therapeutics, Inc, a pharmaceutical company developing and commercializing non-statin, oral medicines for patients with elevated levels of LDL-cholesterol, where he led the development and approval of Nexletol and Nexlizet, the first such medicines approved in almost 20 years. Prior to Esperion, he was President, CEO and Director of Vericel Corporation, (previously named Aastrom Biosciences), former President, COO, and a director of Virtual Radiologics, Inc. (formerly NightHawk Radiology Holdings, Inc.), and former COO and CFO of the original Esperion, until its acquisition by Pfizer in 2004.

Mr. Mayleben earned an MBA, with distinction, from the J.L. Kellogg Graduate School of Management at Northwestern University, and a BBA from the University of Michigan, Ross School of Business.

Tim Mayleben

Tim M. Mayleben

Director

 

Sara Nochur, Ph.D.

Director

Dr. Nochur was appointed to our board of directors March 2021

Dr. Nochur currently serves as Chief Diversity, Equity and Inclusion Officer at Alnylam Pharmaceuticals in Cambridge, MA. Prior to taking on this role in January 2021, she was Chief Regulatory Officer/Vice President and Head of Regulatory Affairs at Alnylam for 14 years. Dr. Nochur has participated as a member of the Management Board of Alnylam and led a world-class team of global regulatory affairs professionals, enabling the multi-national development and approval of three novel drugs for the treatment of rare diseases. At Alnylam, Dr. Nochur and her team successfully leveraged a wide range of key global regulatory pathways, including Orphan Drug Designation, Breakthrough Designation, PRIME Scheme, Pediatric Investigational Plan, Pediatric Voucher, Priority Review, Accelerated Assessment and Accelerated Review.

She has been active in Boston’s biotechnology industry since 1989, and over the years has been a mentor to young professionals as a member of the Healthcare Businesswomen’s Association. Dr. Nochur currently serves on the Advisory Board of Women in the Enterprise of Science and Technology (WEST) and is a host and Chair of the Board of Hospitality Homes, a non-profit organization that provides free or low-cost housing for patients from around the world who seek specialty medical care in Boston.
Dr. Nochur holds a Ph.D. degree in Biochemical Engineering from the Massachusetts Institute of Technology, a master’s degree in Microbiology and bachelor’s degree in Microbiology and Chemistry from the University of Bombay.

Sara

Sara Nochur, Ph.D.

Director